BETTER BIOMARKERS FOR PREDICTING THE INCIDENCE OF HAVING ATHEROSCLEROSIS AND HEART ATTACKS
With
Associate Professor Christina Bursill
Co-Director, Vascular Research Centre,
South Australian Health and Medical Research Institute (SAHMRI) &
Department of Health and Medical Science,
The University of Adelaide, Australia
RESEARCHER PROFILE
Filmed in Adelaide, Australia | April 2025
Associate Professor Christina Bursill started as Co-director of the Vascular Research Centre in January 2017 at the South Australian Health and Medical Research Institute (SAHMRI) and at The University of Adelaide, Department of Health and Medical Science. She currently holds the Lin Huddleston National Heart Foundation fellowship and is a Chief Investigator on the ARC Centre of Excellence for Nanoscale Biophotonics (CNBP).
Assoc Prof Bursill is a vascular biologist with interests and expertise in vascular inflammation, atherosclerosis and angiogenesis. She completed her PhD at The University of Adelaide in lipid metabolism then headed to Oxford University for five years to undergo a postdoctoral post in the Departments of Cardiovascular Medicine and Pathology. Her postdoctoral time triggered her interest in the mechanisms that cause atherosclerosis and in particular the role of small inflammatory proteins called chemokines.
Assoc Prof Bursill returned to Australia in 2007 at the Heart Research Institute (HRI) in Sydney where she led the Immunobiology Group. In 2008, she was awarded a National Heart Foundation Career Development Fellowship. At the HRI A/Prof Bursill developed an interest in high-density lipoproteins (HDL) and through NHMRC and National Heart Foundation funding, investigated novel mechanisms of their action in models of stent biocompatibility, diabetes and wound healing. She also has an interest in using viral gene transfer techniques to over-express proteins that attenuate chemokine activity to suppress atherosclerosis and inflammatory-driven diseases. A/Prof Bursill currently holds NHMRC Ideas, Heart Foundation Vanguard and Diabetes Australia Millenium grant funding.
Recently, Christina has been focusing on finding ways to reduce atherosclerotic heart disease.
Source: Supplied
https://orcid.org/0000-0002-0682-8760
-
Liver cancer biomarkers, risk prediction & progression
Dr. Rodrigo Carlessi is an expert in Cancer Genomics and Molecular Biology, with an extensive track record in liver cancer research. He leads the Cancer Genomics Group within the Liver Disease and Regeneration Laboratory at the Curtin Medical Research Institute. He has an impressive publication record, with 43 manuscripts that have collectively garnered over 2,680 citations. His research leverages cutting-edge genomics and transcriptomics technologies, as well as long-read DNA sequencing, to explore mechanisms, identify biomarkers, and develop therapeutic targets in liver disease and cancer.
-
CASE STUDY Link between levels of extracellular vesicles in the blood and tissue damage caused by diseases
A landmark study led by WEHI and La Trobe University has found a potential new diagnostic marker that could be used to better detect the level of tissue damage in our bodies.
This study revealed, for the first time, a link between levels of EVs in the blood and tissue damage caused by diseases such as leukaemia.
Researchers hope to leverage the critical new insight to develop a blood test to monitor cancer patients with tissue damage, which could, in future, enhance treatment strategies for blood cancers and other diseases.
-
Developing upper limb motor biomarkers of dementia
Kaylee is currently a research fellow with the Wicking Dementia Research and Education Centre at the University of Tasmania. She has recently submitted her PhD thesis, reporting the findings of her research on developing upper limb motor biomarkers of dementia. She has postgrad degrees in physiotherapy and experience working in the community and aged care across Tasmania for several years, where she worked with people with dementia.
